Parkinson disease (PD) is one of the most common neurodegenerative diseases of the elderly in the United States and a substantial source of debility, morbidity, mortality, and medical economic costs, despite the fact that the pathogenetic basis of the movement disorder is largely known and rational treatment for the motor symptoms long available. As highlighted here, part of the reason PD continues to challenge researchers and clinicians is that, simply put, PD is not just a movement disorder. Indeed, the non-motor aspects have greater influence on quality of life, institutionalization rates, and healthcare costs (Chaudhuri et al., 2007) .
Non-motor features occur in virtually all patients with PD (Weintraub et al., 2008) . James Parkinson acknowledged this in his 1817 Essay on the Shaking Palsy, when he described gastrointestinal, neuropsychiatric, sleep and cognitive facets (Parkinson, 2002) . Nonetheless, to this day it is the motor features that define the diagnosis and constitute the focus of treatment. Non-motor features remain under-recognized, under-researched, and under-treated (Chaudhuri et al., 2005) yet they have important implications for our understanding of the pathophysiologic and pathogenetic natures of PD, potentially opening windows to earlier diagnosis and novel treatment strategies, including disease modification and even prevention.
We now know that the by the time Parkinsonism becomes clinically overt, neurodegeneration has been ongoing for some time. Motor symptoms occur only after the majority of nigrostriatal dopaminergic terminals have been lost and compensatory processes overwhelmed. This has led to the notion of a "pre-motor" phase (Stephenson et al., 2009) , during which non-motor manifestations such as cognitive dysfunction, loss of sense of smell, dream enactment behavior, and a variety of autonomic abnormalities may offer key biomarkers of the disease process.
This issue views our understanding of PD through the lens of nonmotor features. By studying them we now appreciate the remarkable heterogeneity of conditions that come under the umbrella of PD. This heterogeneity is evident in pathological and clinical laboratory studies, models of pathogenesis, and clinical presentations. It is by now clear that PD involves many neurological systems, resulting in various patterns of Parkinsonian movements, sensory and autonomic dysfunctions, disturbed sleep, and cognitive and psychiatric abnormalities. Within the autonomic domain, several cardiovascular, gastrointestinal, and genitourinary system components evince physiologic and pathologic changes. In general, the non-motor symptoms of PD and related disorders respond poorly if at all to dopaminergic treatments, indicating likely involvement of other neurotransmitters besides the dopamine.
A classic pathologic hallmark of PD is Lewy bodies, intracytoplasmic inclusions in brainstem monoaminergic neurons, and a classic neurochemical hallmark is striatal dopamine depletion. We believe there is great scientific and clinical importance in answering the question: How are they linked? In modern terms, the question boils down to the relationship between alpha-synucleinopathy and catecholamine neuronal loss. This issue of Neurobiology of Disease includes attempts to address this question.
Lewy bodies and Lewy neurites contain aggregates of the protein α-synuclein, rare families with PD transmitted as an autosomal dominant trait have mutation or replication of the gene encoding alphasynuclein, and genome wide association studies have consistently reported statistical associations between genotypic variations of the alpha-synuclein gene and PD (Valente et al., 2011) . The exact functions of α-synuclein in the neuronal economy remain incompletely understood, although there is evidence that α-synuclein plays roles in synaptic membrane functions, catecholamine biosynthesis, and exocytosis (Dikiy and Eliezer, 2011) .
PD pathology has been observed in neurons of the central autonomic network, including the hypothalamus (Wakabayashi and Takahashi, 1997), dorsal motor nucleus of the vagus (Braak et al., 2004) , and pre-ganglionic sympathetic neurons of the intermediolateral spinal cord (Braak et al., 2007) . PD pathology in post-ganglionic neurons has also been found in several end-organs including the submandibular gland, lower esophagus, duodenum, pancreas, bronchus, larynx, epicardium, adrenal medulla, parathyroid, and ovary (Beach et al., 2010) . Although often seen in the absence of neuronal loss (Braak et al., 2007) , α-synuclein aggregation seems to be a precursor to the motor disorder in PD (Orimo et al., 2008) . According to the Braak hypothesis, before involvement of midbrain substantia nigra dopaminergic neurons, alpha-synuclein deposition occurs in a centripetal, retrograde manner in peripheral monoaminergic neurons and ascends in the brainstem.
Pathological evidence for early involvement of the autonomic nervous system comes from studies of incidental Lewy body disease (ILBD). ILBD is a post-mortem pathological diagnosis based on Lewyrelated pathology in the substantia nigra or pontine locus ceruleus (the main source of norepinephrine in the brain) without a clinical history of Parkinsonism during life. It is thought that ILBD may reflect early PD. In 70-100% of ILBD cases, pathological findings in the sacral and thoracic segments of the spinal cord as well as paravertebral sympathetic ganglia resemble those in PD. ILBD also entails involvement of autonomic innervation in several organ systems reviewed in this issue including the cardiovascular, urinary, and gastrointestinal systems (Bloch et al., 2006; Klos et al., 2006) . This suggests a spectrum of clinical and pre-clinical signs of synucleinopathies, which historically were recognized only by Parkinsonism and if responsive to dopaminergic treatment classified as PD.
Gastrointestinal symptoms can be prominent and disabling nonmotor aspects of PD. Chronic constipation can precede motor signs 
